Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.5385
$0.01853.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.74% | 13.39% | 6.05% | -19.46% | -17.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.30% | -17.47% | -34.67% | -26.82% | -28.28% |
| Operating Income | 25.30% | 17.47% | 34.67% | 26.82% | 28.28% |
| Income Before Tax | 23.01% | 13.45% | 33.17% | 26.19% | 32.89% |
| Income Tax Expenses | 8.11% | -29.73% | 202.17% | -- | 15.63% |
| Earnings from Continuing Operations | 22.98% | 13.46% | 33.09% | 26.27% | 32.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.98% | 13.46% | 33.09% | 26.27% | 32.87% |
| EBIT | 25.30% | 17.47% | 34.67% | 26.82% | 28.28% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 52.80% | 46.84% | 52.44% | 48.44% | 50.72% |
| Normalized Basic EPS | 52.80% | 46.81% | 52.54% | 48.38% | 50.74% |
| EPS Diluted | 52.80% | 46.84% | 52.44% | 48.44% | 50.72% |
| Normalized Diluted EPS | 52.80% | 46.81% | 52.54% | 48.38% | 50.74% |
| Average Basic Shares Outstanding | 63.14% | 62.76% | 40.74% | 43.01% | 36.19% |
| Average Diluted Shares Outstanding | 63.14% | 62.76% | 40.74% | 43.01% | 36.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |